- Home
- SOWG vs KPRX Comparison
SOWG vs KPRX Comparison
Compare SOWG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- KPRX
- Stock Information
- Founded
- SOWG 2010
- KPRX 1998
- Country
- SOWG United States
- KPRX United States
- Employees
- SOWG N/A
- KPRX N/A
- Industry
- SOWG Packaged Foods
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SOWG Consumer Staples
- KPRX Health Care
- Exchange
- SOWG Nasdaq
- KPRX Nasdaq
- Market Cap
- SOWG 10.1M
- KPRX 9.2M
- IPO Year
- SOWG N/A
- KPRX N/A
- Fundamental
- Price
- SOWG $0.83
- KPRX $2.39
- Analyst Decision
- SOWG
- KPRX Strong Buy
- Analyst Count
- SOWG 0
- KPRX 1
- Target Price
- SOWG N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SOWG 257.4K
- KPRX 53.0K
- Earning Date
- SOWG 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- SOWG N/A
- KPRX N/A
- EPS Growth
- SOWG N/A
- KPRX N/A
- EPS
- SOWG N/A
- KPRX N/A
- Revenue
- SOWG $9,271,376.00
- KPRX N/A
- Revenue This Year
- SOWG $6.81
- KPRX N/A
- Revenue Next Year
- SOWG N/A
- KPRX N/A
- P/E Ratio
- SOWG N/A
- KPRX N/A
- Revenue Growth
- SOWG N/A
- KPRX N/A
- 52 Week Low
- SOWG $0.51
- KPRX $2.21
- 52 Week High
- SOWG $11.34
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SOWG 54.02
- KPRX 31.45
- Support Level
- SOWG $0.70
- KPRX $2.21
- Resistance Level
- SOWG $1.01
- KPRX $2.80
- Average True Range (ATR)
- SOWG 0.08
- KPRX 0.14
- MACD
- SOWG 0.01
- KPRX -0.04
- Stochastic Oscillator
- SOWG 44.84
- KPRX 21.65
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.